AstraZeneca Annual Report and Form 20-F Information 2015


Watch this year in review







2015 at a glance


All growth rates at CER.  



Therapy Areas

AstraZeneca is a global, science-led biopharmaceutical business with an on-market portfolio in our chosen therapy areas.




R&D Capabilities

We have distinctive R&D capabilities in small molecules, biologics, immunotherapies, protein engineering and devices.

We also have personalised healthcare and translational science capabilities.


Global presence

We have a strong global commercial presence, with strength in Emerging Markets.


Employees

Our talented employees are committed to achieveing our Purpose in a sustainable way.



61,500 employees worldwide


8,900 employees in R&D


12,500 employees in Manufacturing and Supply


All employee numbers are approximate as at 31 December 2015.



Strategic R&D centres

Increasing our proximity to bioscience clusters and co-locating around three strategic R&D centres.


Cambridge, UK

Gaithersburg, Maryland US

Gothenburg, Sweden




Progressive dividend

Our disciplined capital allocation enables commitment to a progressive dividend.


Net cash shareholder distributions increased to $3,443 million

Dividend per Ordinary Share unchanged

Life-cycle of a medicine

As a global science-led biopharmaceutical company, our activities span the entire life-cycle of a medicine from Research and Development to Manufacturing and Supply to the global Sales and Marketing of primary care and speciality care medicines that transform lives.